A5026634117- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- Gastrointestinal Tumor Research and Treatment
- HER2/EGFR in Cancer Research
- Metastasis and carcinoma case studies
- Microbial Inactivation Methods
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Bone health and osteoporosis research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Multiple and Secondary Primary Cancers
- Nutrition and Health in Aging
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Tracheal and airway disorders
- Cancer Diagnosis and Treatment
- Microfluidic and Bio-sensing Technologies
- Vitamin D Research Studies
- Plasma Applications and Diagnostics
- MicroRNA in disease regulation
- Body Composition Measurement Techniques
- Cancer, Hypoxia, and Metabolism
Copenhagen University Hospital
1997-2024
Rigshospitalet
2014-2024
University of Copenhagen
2001-2023
Zealand University Hospital
2023
Statens Serum Institut
2012
Hvidovre Hospital
1998-2001
4004 Background: The optimum combination curative approach to locally advanced adenocarcinoma of the esophagus and esophago-gastric junction (AEG) is unknown. A key question whether neoadjuvant multimodal therapy, specifically CROSS (carboplatin/paclitaxel, 41.4Gy radiation therapy), superior peri-operative chemotherapeutic regimens including modified MAGIC (epirubicin, cisplatin (oxaliplatin), 5-FU (capecitabine)) more latterly FLOT (docetaxel, 5-FU, leucovorin, oxaliplatin). Neo-AEGIS was...
The optimum curative approach to adenocarcinoma of the oesophagus and oesophagogastric junction is unknown. We aimed compare trimodality therapy (preoperative radiotherapy with carboplatin plus paclitaxel [CROSS regimen]) contemporaneous perioperative chemotherapy regimens (epirubicin cisplatin or oxaliplatin fluorouracil capecitabine [a modified MAGIC regimen] before 2018 fluorouracil, leucovorin, oxaliplatin, docetaxel [FLOT] subsequently).
Neoadjuvant therapy is increasingly the standard of care in management locally advanced adenocarcinoma oesophagus and junction (AEG). In randomised controlled trials (RCTs), MAGIC regimen pre- postoperative chemotherapy, CROSS preoperative chemotherapy combined with radiation, were superior to surgery only RCTs that included AEG but not powered on this cohort. No completed RCT has directly compared neoadjuvant or perioperative chemoradiation. The Neo-AEGIS trial, uniquely AEG, including...
295 Background: The optimum combination curative approach to locally advanced adenocarcinoma of the esophagus and esophago-gastric junction (AEG) remains controversial, specifically whether multimodal therapy or perioperative chemotherapy is superior. Neo-AEGIS was designed as first randomized clinical trial (RCT) directly compare CROSS regimen (carboplatin/paclitaxel, 41.4Gy radiation therapy) with a modified MAGIC (epirubicin, cisplatin (oxaliplatin), 5-FU (capecitabine)) (pre-2018) more...
Background. MicroRNAs (miRNAs) have been associated with prognosis in esophageal cancer, suggesting a role for miRNAs to help guide treatment decisions. Especially, miR-21 and miR-375 investigated as prognostic biomarkers. The aim of this study was evaluate the potential primary squamous cell carcinomas (ESCC) esophagogastric adenocarcinomas (EAC).Material methods. Pre-therapeutic tumor specimens from 195 patients loco-regional cancer treated neoadjuvant or definitive chemoradiotherapy...
Objectives To evaluate whether early reductions in CT perfusion parameters predict response to pre-operative chemotherapy prior surgery for gastroesophageal junction (GEJ) and gastric cancer. Materials Methods Twenty-eight patients with adenocarcinoma of the gastro-esophageal stomach were included. Patients received three series before surgery, each consisting a 3-week cycle intravenous epirubicin, cisplatin or oxaliplatin, concomitant capecitabine peroral. The evaluated scan to, after first...
Abstract Background and study aims Esophageal cancer is on the rise in western world disease has a poor 5-year survival prognosis below 20 %. Electrochemotherapy treatment where chemotherapeutic drug combined with locally applied electrical pulses, order to increase drug’s cytotoxicity malignant cells. This presents first results electrochemotherapy esophageal cancer. Patients methods In this first-in-human trial, six patients advanced were treated using intravenous bleomycin. All side...
Gotfredsen, Anders, Lene Bæksgaard, and Jannik Hilsted.Body composition analysis by DEXA using dynamically changing samarium filtration. J. Appl. Physiol.82(4): 1200–1209, 1997.—Dual-energy X-ray absorptiometry (DEXA) has a high accuracy for body but is influenced beam hardening other error sources in the extremes of measurement. To compensate hardening, Norland XR-36 introduces filtration system, which depends on current-absorber thickness. With this system we found good agreement ( r =...
Longterm survival after curative resection for adenocarcinoma at the gastro-esophageal junction (GEJ) range between 18% and 50%. In pivotal Intergroup-0116 Phase III trial by Macdonald et all, adjuvant chemoradiotherapy improved both disease-free overall in curatively resected patients with mainly gastric adenocarcinoma. We compared data adeno-carcinoma solely (GEJ), treated surgery alone or chemoradio-therapy.From 2003 to 2009, 211 underwent resection. Surgery was performed 95 pa-tients 116...
Perioperative 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) is recommended in resectable esophagogastric adenocarcinoma based on randomised trials. However, the effectiveness of FLOT routine clinical practice remains unknown as trials are subject to selection bias limiting their generalisability. The aim this study was evaluate implementation real-world patients.
Abstract Background Gastric and gastroesophageal junction (GEJ) cancer represents a significant global health challenge, with high recurrence rates poor survival outcomes. This study investigates circulating tumor DNA (ctDNA) as biomarker for assessing risk in patients resectable gastric GEJ adenocarcinomas (AC). Methods Patients AC, undergoing perioperative chemotherapy surgery, were prospectively enrolled. Serial plasma samples collected at baseline, after one cycle of chemotherapy,...
Calcium electroporation (CaEP) is a novel cancer therapy wherein high intracellular calcium levels, facilitated by reversible electroporation, trigger tumor necrosis. This study aimed to establish safety with CaEP within esophageal cancer. Patients non-curable were included at Copenhagen University Hospital Rigshospitalet in 2021 and 2022. In an outpatient setting, gluconate was injected intratumorally followed applied endoscopic electrode. The primary endpoint the prevalence of adverse...
To evaluate the feasibility of a new liquid fiducial marker for use in image-guided radiotherapy oesophageal cancer.Liquid markers were implanted patients with metastatic or inoperable locally advanced gastro-oesophageal junction cancer receiving radiotherapy. Markers using conventional gastroscope equipped 22 G Wang needle. Marker visibility was evaluated on fluoroscopy, CT, MRI and cone beam CT scans.Liquid (n = 16) injected four patients. No Grade 2 worse adverse events observed relation...
Computed Tomography (CT) Perfusion is an evolving method to visualize perfusion in organs and tissue. With the introduction of multidetector CT scanners, it now possible cover up 16 cm one rotation, thereby making scan entire such as liver with a fixed table position. Advances reconstruction algorithms make reduce radiation dose for each examination acceptable levels. Regarding abdominal imaging, still considered research tool, but several studies have proven reliable non-invasive technique...